Add to ORKGMulticenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cance
Background: Irinotecan is an active drug in colorectal cancer. In patients with liver metastases, he...
This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as ...
Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal ca...
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after...
Background: In this study, we attempted to determine the efficacy and toxicity of decreas-ing dosage...
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or...
Background: The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profil...
Irinotecan and raltitrexed are active agents in advanced colorectal cancer (ACC) and preclinical dat...
Objectives: To evaluate three technologies for the management of advanced colorectal cancer: (1) fi...
<p><b>Copyright information:</b></p><p>Taken from "Phase I/II study of first-line irinotecan combine...
Full list of author information is available at the end of the articleBackground Colorectal cancer, ...
Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating sche...
Background: Irinotecan is a topoisomerase I inhibitor that prolongs survival as second- line therapy...
BACKGROUND: The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluoro...
Full list of author information is available at the end of the articleBackground In 2008, the number...
Background: Irinotecan is an active drug in colorectal cancer. In patients with liver metastases, he...
This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as ...
Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal ca...
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after...
Background: In this study, we attempted to determine the efficacy and toxicity of decreas-ing dosage...
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or...
Background: The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profil...
Irinotecan and raltitrexed are active agents in advanced colorectal cancer (ACC) and preclinical dat...
Objectives: To evaluate three technologies for the management of advanced colorectal cancer: (1) fi...
<p><b>Copyright information:</b></p><p>Taken from "Phase I/II study of first-line irinotecan combine...
Full list of author information is available at the end of the articleBackground Colorectal cancer, ...
Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating sche...
Background: Irinotecan is a topoisomerase I inhibitor that prolongs survival as second- line therapy...
BACKGROUND: The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluoro...
Full list of author information is available at the end of the articleBackground In 2008, the number...
Background: Irinotecan is an active drug in colorectal cancer. In patients with liver metastases, he...
This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as ...
Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal ca...
